{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:19:16Z","timestamp":1792289956168,"version":"4.4.0"},"reference-count":81,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"unspecified","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Agence R\u00e9gionale de Sant\u00e9 Auvergne-Rh\u00f4ne-Alpes","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"\u201cPrix Herv\u00e9 Fridman\u201d 2022","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100012097","name":"Association Vaincre le M\u00e9lanome","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100012097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"crossref","award":["FDM202306017085"],"award-info":[{"award-number":["FDM202306017085"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Institut National contre le Cancer","award":["INCA-DGOS PRTK Melonet DA 2021-021"],"award-info":[{"award-number":["INCA-DGOS PRTK Melonet DA 2021-021"]}]},{"name":"ARC sign\u2019it 2019 Birdman","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100004099","name":"Ligue Nationale contre le Cancer","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ITMO Cancer of Aviesan","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Association Melarnaud","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Lyon Integrated Research Institute in Cancer","award":["SIRIC LYriCAN INCa-DGOS-Inserm_12563 and LYriCAN+"],"award-info":[{"award-number":["SIRIC LYriCAN INCa-DGOS-Inserm_12563 and LYriCAN+"]}]},{"name":"IRICE R\u00e9gion Auvergne Rh\u00f4ne-Alpes","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100005897","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100005897","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ERiCAN program of Fondation MSD-Avenir","award":["DS-2018-0015"],"award-info":[{"award-number":["DS-2018-0015"]}]},{"name":"Institut Convergence PLAsCAN","award":["ANR-17-CONV-0002"],"award-info":[{"award-number":["ANR-17-CONV-0002"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,5,15]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Melanoma shows one of the highest response rates to immune checkpoint inhibitors (ICIs), yet nearly half of patients experience primary or acquired resistance. While immune contexture strongly influences therapeutic efficacy, tumor cell-intrinsic features are increasingly recognized as key regulators of antitumor immunity. In particular, intratumoral heterogeneity driven by melanoma cell plasticity underlies diverse immune escape mechanisms. How this plasticity shapes ICI outcomes in patients remains poorly defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Tumor cell states and immune contexture were assessed in 57 primary cutaneous melanomas from stage III patients, collected prior to adjuvant anti-programmed cell death protein-1 (anti-PD-1) therapy and stratified according to 2-year relapse status (33 relapse-free, 24 relapsed). Whole slide multiplex immunofluorescence was combined with spatial transcriptomics (Visium, n=4) to investigate the spatial architecture of melanoma cell states, T cells, tumor-associated macrophages (TAMs), dendritic cell subsets, and tertiary lymphoid structures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Unsupervised clustering of melanoma cells identified distinct phenotypic states that formed spatially restricted homotypic patches. From these data, we defined a melanoma plasticity ratio (undifferentiated\/differentiated tumor patches), which was significantly associated with reduced relapse-free survival. Integrated immune analyses recapitulated prognostically distinct immunotypes, with macrophage subsets displaying striking spatial compartmentalization. Antitumoral macrophages preferentially infiltrated differentiated melanoma regions, while protumoral macrophages localized to undifferentiated patches. Spatial transcriptomics confirmed that melanoma cell states tightly shape the neighboring immune microenvironment, with macrophages emerging as pivotal players. Their polarization was further influenced by tumor-derived signals in addition to microenvironmental cues (interferon-gamma, hypoxia). Entropy-based integration of melanoma cell states, TAMs, and T cell subsets uncovered two dominant spatial ecosystems with opposing associations to ICI efficacy. Ecosystems enriched in differentiated melanoma cells, programmed death-ligand 1 (PD-L1)\n                      <jats:sup>+<\/jats:sup>\n                      TAMs, and PD-1\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      , and CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells correlated with favorable outcomes, whereas ecosystems composed of undifferentiated melanoma cells with PD-L1\n                      <jats:sup>\u2212<\/jats:sup>\n                      protumoral TAMs and PD-1\n                      <jats:sup>\u2212<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells were associated with relapse.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study uncovers how cancer cell plasticity shapes spatially organized tumor-immune ecosystems that critically modulate adjuvant ICI efficacy in melanoma. These findings highlight melanoma cell plasticity as a key driver of immune evasion via macrophages reprogramming, through targetable interactions that may represent novel therapeutic avenues to enhance ICI efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014030","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:21:51Z","timestamp":1781792511000},"page":"e014030","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Melanoma cell states shape spatial tumor-immune ecosystems to dictate the efficacy of anti-PD1 immunotherapy"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7855-4930","authenticated-orcid":false,"given":"F\u00e9lix K","family":"Pham","sequence":"first","affiliation":[{"name":"\u201cCancer cell Plasticity in Melanoma\u201d lab, \u201cEquipe labellis\u00e9e Ligue Contre le Cancer\u201d, INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Centre de Recherche en Canc\u00e9rologie de Lyon, Lyon, France"},{"name":"Dermatology Department, Hospices Civils de Lyon, Pierre B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Dufeu","sequence":"additional","affiliation":[{"name":"\u201cCancer cell Plasticity in Melanoma\u201d lab, \u201cEquipe labellis\u00e9e Ligue Contre le Cancer\u201d, INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Centre de Recherche en Canc\u00e9rologie de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Benboubker","sequence":"additional","affiliation":[{"name":"\u201cCancer cell Plasticity in Melanoma\u201d lab, \u201cEquipe labellis\u00e9e Ligue Contre le Cancer\u201d, INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Centre de Recherche en Canc\u00e9rologie de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Grimont","sequence":"additional","affiliation":[{"name":"\u201cCancer cell Plasticity in Melanoma\u201d lab, \u201cEquipe labellis\u00e9e Ligue Contre le Cancer\u201d, INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Centre de Recherche en Canc\u00e9rologie de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Lhorisson","sequence":"additional","affiliation":[{"name":"INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Lyon Immunotherapy for Cancer Laboratory (LICL), Centre de Recherche en Canc\u00e9rologie de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Berthet","sequence":"additional","affiliation":[{"name":"INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Lyon Immunotherapy for Cancer Laboratory (LICL), Centre de Recherche en Canc\u00e9rologie de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Donzel","sequence":"additional","affiliation":[{"name":"Pathology Department, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Schneider","sequence":"additional","affiliation":[{"name":"Plateforme de bio-informatique Gilles Thomas, Centre de Recherche en Canc\u00e9rologie de Lyon, Centre L\u00e9on B\u00e9rard, INSERM U1052-CNRS UMR5286, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Fondation Synergie Lyon Cancer, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Tonon","sequence":"additional","affiliation":[{"name":"Plateforme de bio-informatique Gilles Thomas, Centre de Recherche en Canc\u00e9rologie de Lyon, Centre L\u00e9on B\u00e9rard, INSERM U1052-CNRS UMR5286, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Fondation Synergie Lyon Cancer, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Doffin","sequence":"additional","affiliation":[{"name":"INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Lyon Immunotherapy for Cancer Laboratory (LICL), Centre de Recherche en Canc\u00e9rologie de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Boivin","sequence":"additional","affiliation":[{"name":"\u201cCancer cell Plasticity in Melanoma\u201d lab, \u201cEquipe labellis\u00e9e Ligue Contre le Cancer\u201d, INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Centre de Recherche en Canc\u00e9rologie de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Durand","sequence":"additional","affiliation":[{"name":"\u201cCancer cell Plasticity in Melanoma\u201d lab, \u201cEquipe labellis\u00e9e Ligue Contre le Cancer\u201d, INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Centre de Recherche en Canc\u00e9rologie de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Dubois","sequence":"additional","affiliation":[{"name":"INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Lyon Immunotherapy for Cancer Laboratory (LICL), Centre de Recherche en Canc\u00e9rologie de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lopez","sequence":"additional","affiliation":[{"name":"\u201cCancer cell Plasticity in Melanoma\u201d lab, \u201cEquipe labellis\u00e9e Ligue Contre le Cancer\u201d, INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Centre de Recherche en Canc\u00e9rologie de Lyon, Lyon, France"},{"name":"Hospices Civils de Lyon, Pierre B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Caux","sequence":"additional","affiliation":[{"name":"INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Lyon Immunotherapy for Cancer Laboratory (LICL), Centre de Recherche en Canc\u00e9rologie de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4160-8867","authenticated-orcid":false,"given":"Jenny","family":"Valladeau-Guilemond","sequence":"additional","affiliation":[{"name":"INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Lyon Immunotherapy for Cancer Laboratory (LICL), Centre de Recherche en Canc\u00e9rologie de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Eberhardt","sequence":"additional","affiliation":[{"name":"\u201cCancer cell Plasticity in Melanoma\u201d lab, \u201cEquipe labellis\u00e9e Ligue Contre le Cancer\u201d, INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Centre de Recherche en Canc\u00e9rologie de Lyon, Lyon, France"},{"name":"Dermatology Department, Hospices Civils de Lyon, Pierre B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Dalle","sequence":"additional","affiliation":[{"name":"\u201cCancer cell Plasticity in Melanoma\u201d lab, \u201cEquipe labellis\u00e9e Ligue Contre le Cancer\u201d, INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Centre de Recherche en Canc\u00e9rologie de Lyon, Lyon, France"},{"name":"Dermatology Department, Hospices Civils de Lyon, Pierre B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-918X","authenticated-orcid":false,"given":"Julie","family":"Caramel","sequence":"additional","affiliation":[{"name":"\u201cCancer cell Plasticity in Melanoma\u201d lab, \u201cEquipe labellis\u00e9e Ligue Contre le Cancer\u201d, INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, Centre de Recherche en Canc\u00e9rologie de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"2026061803551688000_14.6.e014030.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2407417"},{"key":"2026061803551688000_14.6.e014030.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.10000"},{"key":"2026061803551688000_14.6.e014030.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.10.038"},{"key":"2026061803551688000_14.6.e014030.4","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCELL.2019.01.003"},{"key":"2026061803551688000_14.6.e014030.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.12.021"},{"key":"2026061803551688000_14.6.e014030.6","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1158\/0008-5472.CAN-23-3918","article-title":"Single-Cell Analyses Reveal a Functionally Heterogeneous Exhausted CD8+ T-cell Subpopulation That Is Correlated with Response to Checkpoint Therapy in Melanoma","volume":"85","author":"Mahuron","year":"2025","journal-title":"Cancer Res"},{"key":"2026061803551688000_14.6.e014030.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.03.012"},{"key":"2026061803551688000_14.6.e014030.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0085-8"},{"key":"2026061803551688000_14.6.e014030.9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/2326-6066.CIR-24-0421","article-title":"The Spatial Organization of cDC1 with CD8+ T Cells is Critical for the Response to Immune Checkpoint Inhibitors in Patients with Melanoma","volume":"13","author":"Gobbini","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"2026061803551688000_14.6.e014030.10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature New Biol"},{"key":"2026061803551688000_14.6.e014030.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.02.001"},{"key":"2026061803551688000_14.6.e014030.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.07.007"},{"key":"2026061803551688000_14.6.e014030.13","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade2292"},{"key":"2026061803551688000_14.6.e014030.14","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1038\/s41467-024-50478-8","article-title":"A single-cell pan-cancer analysis to show the variability of tumor-infiltrating myeloid cells in immune checkpoint blockade","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"2026061803551688000_14.6.e014030.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01792-2"},{"key":"2026061803551688000_14.6.e014030.16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-0363"},{"key":"2026061803551688000_14.6.e014030.17","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ccell.2025.01.012","article-title":"Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer","volume":"43","author":"Chen","year":"2025","journal-title":"Cancer Cell"},{"key":"2026061803551688000_14.6.e014030.18","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404"},{"key":"2026061803551688000_14.6.e014030.19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0095"},{"key":"2026061803551688000_14.6.e014030.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958"},{"key":"2026061803551688000_14.6.e014030.21","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-36979-y","article-title":"The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat Commun"},{"key":"2026061803551688000_14.6.e014030.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.01.009"},{"key":"2026061803551688000_14.6.e014030.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502583"},{"key":"2026061803551688000_14.6.e014030.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0154-4"},{"key":"2026061803551688000_14.6.e014030.25"},{"key":"2026061803551688000_14.6.e014030.26","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201505971"},{"key":"2026061803551688000_14.6.e014030.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.06.025"},{"key":"2026061803551688000_14.6.e014030.28","doi-asserted-by":"publisher","DOI":"10.1101\/gad.329771.119"},{"key":"2026061803551688000_14.6.e014030.29","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nature11538","article-title":"Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation","volume":"490","author":"Landsberg","year":"2012","journal-title":"Nature New Biol"},{"key":"2026061803551688000_14.6.e014030.30","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17739-8","article-title":"Reversal of pre-existing NGFR-driven tumor and immune therapy resistance","volume":"11","author":"Boshuizen","year":"2020","journal-title":"Nat Commun"},{"key":"2026061803551688000_14.6.e014030.31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.873116","article-title":"Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma","volume":"13","author":"Benboubker","year":"2022","journal-title":"Front Immunol"},{"key":"2026061803551688000_14.6.e014030.32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003484","article-title":"ZEB1 transcription factor promotes immune escape in melanoma","volume":"10","author":"Plaschka","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026061803551688000_14.6.e014030.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.04.012"},{"key":"2026061803551688000_14.6.e014030.34","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/s43018-025-00963-w","article-title":"MCSP+ metastasis founder cells activate immunosuppression early in human melanoma metastatic colonization","volume":"6","author":"Guetter","year":"2025","journal-title":"Nat Cancer"},{"key":"2026061803551688000_14.6.e014030.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.11.037"},{"key":"2026061803551688000_14.6.e014030.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2005.04.019"},{"key":"2026061803551688000_14.6.e014030.37","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28801-y","article-title":"Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma","volume":"13","author":"Capparelli","year":"2022","journal-title":"Nat Commun"},{"key":"2026061803551688000_14.6.e014030.38","doi-asserted-by":"publisher","DOI":"10.1101\/gad.406406"},{"key":"2026061803551688000_14.6.e014030.39","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2491"},{"key":"2026061803551688000_14.6.e014030.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.08.018"},{"key":"2026061803551688000_14.6.e014030.41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-2373"},{"key":"2026061803551688000_14.6.e014030.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03010-7"},{"key":"2026061803551688000_14.6.e014030.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.017"},{"key":"2026061803551688000_14.6.e014030.44","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-020-0547-3"},{"key":"2026061803551688000_14.6.e014030.45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0010"},{"key":"2026061803551688000_14.6.e014030.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-023-00881-0"},{"key":"2026061803551688000_14.6.e014030.47","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1466-822X.2003.00015.x","article-title":"A tribute to Claude Shannon (1916\u20132001) and a plea for more rigorous use of species richness, species diversity and the \u2018Shannon\u2013Wiener\u2019 Index","volume":"12","author":"Spellerberg","year":"2003","journal-title":"Glob Ecol Biogeogr"},{"key":"2026061803551688000_14.6.e014030.48","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0007-y"},{"key":"2026061803551688000_14.6.e014030.49","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008125","article-title":"Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma","volume":"12","author":"Versluis","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026061803551688000_14.6.e014030.50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37822-0"},{"key":"2026061803551688000_14.6.e014030.51","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/pcmr.13189","article-title":"The classification of melanocytic gene signatures","volume":"37","author":"Hu","year":"2024","journal-title":"Pigment Cell Melanoma Res"},{"key":"2026061803551688000_14.6.e014030.52","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01273-7"},{"key":"2026061803551688000_14.6.e014030.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2022.04.008"},{"key":"2026061803551688000_14.6.e014030.54","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00921-5"},{"key":"2026061803551688000_14.6.e014030.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.010"},{"key":"2026061803551688000_14.6.e014030.56","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-024-01045-4"},{"key":"2026061803551688000_14.6.e014030.57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.10.4965"},{"key":"2026061803551688000_14.6.e014030.58","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2000.00997.x"},{"key":"2026061803551688000_14.6.e014030.59","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-57603-1","article-title":"Interleukin-16 enhances anti-tumor immune responses by establishing a Th1 cell-macrophage crosstalk through reprogramming glutamine metabolism in mice","volume":"16","author":"Wen","year":"2025","journal-title":"Nat Commun"},{"key":"2026061803551688000_14.6.e014030.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.05.004"},{"key":"2026061803551688000_14.6.e014030.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.016"},{"key":"2026061803551688000_14.6.e014030.62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01132","article-title":"Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma","volume":"9","author":"Figueiredo","year":"2018","journal-title":"Front Immunol"},{"key":"2026061803551688000_14.6.e014030.63","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1846915","article-title":"MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma","volume":"9","author":"de Azevedo","year":"2020","journal-title":"Oncoimmunology"},{"key":"2026061803551688000_14.6.e014030.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.11.007"},{"key":"2026061803551688000_14.6.e014030.65","doi-asserted-by":"crossref","DOI":"10.1016\/j.xgen.2025.100764","article-title":"Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures","volume":"5","author":"Di Giovannantonio","year":"2025","journal-title":"Cell Genom"},{"key":"2026061803551688000_14.6.e014030.66","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00031-4"},{"key":"2026061803551688000_14.6.e014030.67","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/1878-0261.13450","article-title":"Dual VEGFA\/BRAF targeting boosts PD-1 blockade in melanoma through GM-CSF-mediated infiltration of M1 macrophages","volume":"17","author":"Comunanza","year":"2023","journal-title":"Mol Oncol"},{"key":"2026061803551688000_14.6.e014030.68","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1073-3"},{"key":"2026061803551688000_14.6.e014030.69","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s43018-025-00929-y","article-title":"Systemic rewiring of dendritic cells by melanoma-secreted midkine impairs immune surveillance and response to immune checkpoint blockade","volume":"6","author":"Catena","year":"2025","journal-title":"Nat Cancer"},{"key":"2026061803551688000_14.6.e014030.70","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.tcb.2025.01.009","article-title":"Decoding melanoma\u2019s cellular mosaic to unlock immunotherapy potential","volume":"35","author":"Pozniak","year":"2025","journal-title":"Trends Cell Biol"},{"key":"2026061803551688000_14.6.e014030.71","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01141-9"},{"key":"2026061803551688000_14.6.e014030.72","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/cac2.12316","article-title":"The theory of tumor ecosystem","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun"},{"key":"2026061803551688000_14.6.e014030.73","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41586-022-05242-7","article-title":"A cellular hierarchy in melanoma uncouples growth and metastasis","volume":"610","author":"Karras","year":"2022","journal-title":"Nature New Biol"},{"key":"2026061803551688000_14.6.e014030.74","first-page":"1","article-title":"snPATHO-seq, a versatile FFPE single-nucleus RNA sequencing method to unlock pathology archives","volume":"7","author":"Wang","year":"2024","journal-title":"Commun Biol"},{"key":"2026061803551688000_14.6.e014030.75","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-01033-z"},{"key":"2026061803551688000_14.6.e014030.76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01932-3"},{"key":"2026061803551688000_14.6.e014030.77","doi-asserted-by":"crossref","DOI":"10.1038\/s41525-021-00196-7","article-title":"STAT1 gain-of-function heterozygous cell models reveal diverse interferon-signature gene transcriptional responses","volume":"6","author":"Scott","year":"2021","journal-title":"NPJ Genom Med"},{"key":"2026061803551688000_14.6.e014030.78","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.178456","article-title":"IFN-signaling gene expression as a diagnostic biomarker for monogenic interferonopathies","volume":"9","author":"Adang","year":"2024","journal-title":"JCI Insight"},{"key":"2026061803551688000_14.6.e014030.79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051862","article-title":"Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization","volume":"7","author":"Budczies","year":"2012","journal-title":"PLoS ONE"},{"key":"2026061803551688000_14.6.e014030.80","doi-asserted-by":"crossref","unstructured":"Mainali KP , Slud E . CooccurrenceAffinity: an r package for computing a novel metric of affinity in co-occurrence data that corrects for pervasive errors in traditional indices. Ecology [Preprint] 2022. doi:10.1101\/2022.11.01.514801","DOI":"10.1101\/2022.11.01.514801"},{"key":"2026061803551688000_14.6.e014030.81","unstructured":"Pham F , Dufeu M . Data from: melanoma cell states shape spatial tumor-immune ecosystems to dictate the efficacy of anti-PD1 immunotherapy. Gene Expression Omnibus."}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:21:58Z","timestamp":1781792518000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":81,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,18]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/jitc-2025-014030"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014030","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}